secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001599298-25-000128
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ivonescimab HARMONi PFS HR 0.52, NMPA approval; Summit Q2 net loss $565.7M
--------------------------------------------------------------------------

- HARMONi PFS HR 0.52 (p<0.00001); OS trend HR 0.79 (p=0.057); BLA filing planned.
- Ivonescimab monotherapy approved by NMPA for 1L PD-L1 positive advanced NSCLC in China.
- HARMONi-6: ivonescimab + chemo superior to tislelizumab + chemo in 1L squamous NSCLC.
- Cash & equivalents $297.9M (down from $412.3M); ATM offering of up to $360M.
- GAAP net loss $565.7M ($0.76/sh); non-GAAP $86.9M ($0.12/sh); stock modification $466.6M non-cash.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929825000128/0001599298-25-000128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929825000128/smmt-20250811.htm
  HTML page:      https://secwatch.observer/filing/0001599298-25-000128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer